Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the … | News

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the data submitted in support of the Tebipenem HBr NDA were insufficient to obtain FDA approval; (2) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (3) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggregated investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA and NY Bar

[email protected]

310-692-8883

www.portnoylaw.com

Attorney Advertising

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.